Monograph
S01BC10 - Nepafenac |
Not porphyrinogenic |
NP |
Rationale
Nepafenac is administered locally in the eye and hepatic exposure is insignificant.
Chemical description
Benzophenone
Therapeutic characteristics
Nepafenac is a non-steroid anti-inflammatory prodrug used in the treatment of postoperative pain and inflammation associated with cataract surgery (SPC). It is administered as eye drops.
Hepatic exposure
Following the 3 times daily dosing of nepafenac eye drops in both eyes, maximal plasma concentration of nepafenac and amfenak were in the order of 0,5 ng/ml (SPC) which is well below 1,0 µM concentration and hepatic exposure is therefore regarded as insignificant.
Metabolism and pharmacokinetics
Nepafenac is converted by ocular tissue hydrolases to the active drug amfenac. Amfenac is further hydroxylated, bound to glucoronic acid and excreted as glucuronide conjugates (SPC).
In vitro studies show that neither nepafenac nor amfenac show inhibitory effects on the major CYP450 metabolizing enzymes (CYP3A4, CYP2C9) (SPC).
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (eMC). Nevanac. Summary of Product Characteristics (SPC).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024